For analysis of thrombin generation, a mixed inhibition model 1 was fit to each time course of AMC production (►Scheme 1) and 7 differential equations for the reactants and product were formulated: 
In these equations, FXa is the free factor Xa concentration, S is the concentration of Pefafluor Xa, I is the concentration of inhibitor (apixaban or rivaroxaban), FXa·S is the factor Xa-Pefafluor Xa complex, FXa·I is the factor Xa-inhibitor complex, and FXa·S·I is the ternary factor Xa-Pefafluor Xa-inhibitor complex.
Plots of AMC concentration versus time were analyzed by numerical integration using Berkeley Madonna Software (University of California, Berkeley, CA).
2 The 3-time courses obtained with each inhibitor were fit simultaneously with the assumption that the rate constants k 1 , j 1 , and k 2 are equal for all of the reactions regardless of whether the inhibitor is present. Therefore, k 1 , j 1 , and k 2 were fit globally, whereas k 3 , j 3 , k 4 and j 4 were fit individually. After analysis of the 6 sets of data, the fitted rate constants were averaged. Once the best-fit rate constants were determined, the theoretical dissociation constants for each inhibitor were calculated for free factor Xa (K Xa1 ¼ j 3 /k 3 ) and for the factor Xa-substrate complex (K Xa2 ¼ j 4 /k 4 ). The individual rate constants for association and dissociation of the inhibitors with factor Xa incorporated into the prothrombinase complex were determined by measuring thrombin generation to infer residual factor Xa activity in real-time. Thrombin generation was quantified using DAPA, a probe that specifically inhibits thrombin and exhibits increased fluorescence on doing so, 3 with or without the inhibitors. The time course profiles generated were again fit using a mixed inhibition model 1 (►Scheme 2), wherein all forms of factor Xa (E), both free or within prothrombinase, could interact with the inhibitor (I). Prothrombin (P) activation by prothrombinase was limited to the meizothrombin (M) pathway. Ratcheting of meizothrombin, a phenomenon whereby meizothrombin alters its conformation and renders the second cleavage by prothrombinase more effective, was included (k 5 , j 5 in ►Scheme 2) to be consistent with current models of prothrombinase. 4 The inhibition rate constants for the binding of the inhibitors to prothrombinase when it is in complex with either form of meizothrombin were kept the same. In addition, the fluorescence quantum yield of meizothrombin was taken to be 1.5 times that of thrombin. 5, 6 Based on this model, 13
differential equations for the reactants and product were formulated: 
The total fluorescence signal (FS) was taken as the sum of both forms of meizothrombin with the coefficient of 1.5 relative to thrombin (T) (Eq. 21).
Plots of thrombin concentration versus time were analyzed by numerical integration with Berkeley Madonna Software (University of California, Berkeley, CA).
2 The data were fit in 4 separate rounds. In the first round, each set of data containing the full range of concentrations of each of the inhibitors was fit individually with little to no imposed restriction. This was repeated 3 times for each inhibitor. The rate constants of the main reaction that do not involve the inhibitor (k x and j x ) were assumed to be the same. Therefore, during the second round of fitting, the 6 k x and j x values estimated from the initial analysis were averaged and allowed to fluctuate by 15% of the mean when fitting the time course in the absence of the inhibitors.
Once the best-fit k x and j x values for each set of data were obtained (►Table S1), they were fixed and used in the third round of fitting. In this round, time course profiles with all concentrations of inhibitor were fit simultaneously with no restrictions imposed on the inhibition rate constants. The 3 sets of ki x and ji x values for each inhibitor were then averaged, and in the final round of fitting, were allowed to fluctuate by 15% of the mean. Using the estimated best-fit rate constants, the theoretical dissociation constants for each inhibitor were calculated for prothrombinase without prothrombin (K Pase1 ¼ ji 1 /ki 1 ), prothrombinase in complex with prothrombin (K Pase2 ¼ ji 2 /ki 2 ) and for prothrombinase in complex with either form of meizothrombin (K Pase3 ¼ ji 3 /ki 3 ).
To determine whether the divergent effects of rivaroxaban and apixaban on the coagulation assays are due to differential inhibition of factor Xa leading to differences in substrate recognition, a prothrombin derivative, rMZ, which can only be cleaved at Arg320, was used as the substrate so that initial cleavage at this site could be examined in isolation.
7 rMZ activation by prothrombinase was monitored and the data were analyzed under conditions identical to those used with wild-type prothrombin. The model shown in ►Scheme 1 was used to describe this reaction, where the substrate (S) was replaced with rMZ and the product (P) was replaced with rMZa. The theoretical dissociation constants for rivaroxaban or apixaban were again calculated using the best-fit rate constants determined as described above. The values represent mean AE standard deviation (n ¼ 6). The units of the on-rates (k 1 , k 3 , k 5 , and k 6 ) are nM -1 ·second À1 , and off-rates (j 1 , j 3 , j 5 , and j 6 ) and turnover rates (k 2 , k 4 , and k 7 ) are second À1 .
